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Receptor-targeting fluorescence imaging and
theranostics using a graphene oxide based
supramolecular glycocomposite†
Ding-Kun Ji,‡a Yue Zhang,‡ab Yi Zang,*b Wang Liu,c Xiongwen Zhang,c Jia Li,*b
Guo-Rong Chen,a Tony D. Jamesd and Xiao-Peng He*a
Intercellular glycoligand-receptor interactions are implicated in a number of disease-related processes.
Eﬀective tools that target these receptors may facilitate disease theranostics. However, owing to their
low binding aﬃnity, multivalent presentation of glycoligands is needed to increase the avidity with
transmembrane receptors. While previous strategies focus on the covalent coupling of glycoligands to a
synthetic backbone, we show here that the use of graphene oxide (GO) greatly enhances the cellular
and tissue imaging ability of a small-molecule fluorescence glycoprobe. We determine that GO with an
optimum size may serve as a clustering platform to reinforce the interaction of the glycoprobe with its
selective receptor on a cancer cell. This phenomenon has been consistently observed with the
xenograft tissue of a tumor-bearing mouse. Using this principle we have further constructed a
supramolecular glycocomposite by co-assembling the glycoprobe and an anticancer drug onto a single
GO surface. In addition to imaging ability, this material displays improved toxicity for liver cancer cells
that over express the glycoprotein receptor, when compared to the control cells.
Introduction
Intercellular ligand–receptor interactions are crucial for the
initiation of numerous physiological and pathological events.
For example, the galectins, which recognize galactose-terminated
glycoconjugates, are over-secreted during the progression of
cancer, inflammation and heart disease. In the process of
influenza virus invasion, sialic acid-terminated oligosaccharides
of human cells are recognized by the hemagglutinins expressed
on the viral particle surface, facilitating virus invasion. Another
class of transmembrane receptors are the C-type lectins, which
are distributed on specific types of cells.1–3 They can interact
with selective glycoligands (glycans) to promote human diseases.4,5
As a consequence, effective methods to probe these dynamic
events directly on the cellular level are important for the
advancement of chemical glycobiology and disease theranostics.
Considering the low aﬃnity between a glycoligand and the
receptor, the ligands require multivalent presentation to
increase the binding avidity. Many elegant methods have been
developed to construct multivalent glycopolymers6,7 and glyco-
conjugates8 to address the avidity. However, these methods
mainly focus on the covalent coupling of glycoligands to a
synthetic backbone, which might increase the complexity of
probe preparation. Recently, we9–13 and others14–21 have shown
that fluorogenic composite materials (FCMs) that feature a
material substrate (especially graphene oxide [GO]) on which
a fluorophore-tagged ligand is self-assembled are emerging as
promising biosensing materials owing to their ease of prepara-
tion and manipulation, low cost and ability to capture receptor
expression of live cells.
Here, we uncover that the addition of GO greatly enhances
the receptor-targeting cellular imaging eﬀect of a small-molecule
fluorescence glycoprobe. We determined that GO with an optimum
size may act as a clustering platform to reinforce the selective
interaction between the glycoprobe and receptor on a cancer cell.
This phenomenon has been consistently observed with the
xenograft tissue of a tumor-bearing mouse. Using this principle
we have further constructed a supramolecular glycocomposite
by co-assembling the glycoprobe and an anticancer drug onto a
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single GO surface. In addition to imaging ability, this material
displays improved toxicity for liver cancer cells that over express
the glycoprotein receptor, when compared to the control cells
without receptor expression (Fig. 1).
Results and discussion
The glycoprobe (DK1, Fig. 1a) was synthesized by a click
reaction between alkynyl galactoside 1 and an azido dicyano-
methylene 2 (Fig. 1a), according to a previous protocol.22 The
galactosyl moiety can be recognized by the transmembrane
asialoglycoprotein receptor (ASGPr) selectively expressed on
hepatocytes (we used Hep-G2, a human hepatoma cell line),
while the fluorophore can produce an optical signal and self-
assemble to the surface of GO via p-stacking and other forces of
interaction such as van der Waals and hydrogen-bonding.9–14
The fluorescence imaging of DK1 for ASGPr-rich Hep-G223 was
carried out and optimized in the absence and presence of a
series of GOs with different sizes (G0: 0–10 nm; G1: 50–200 nm;
G2: 200–500 nm; G3: 500–1000 nm). The atomic force micro-
scopic characterization of the GOs is shown in Fig. S1 (ESI†).
We observed that, among the GOs used, the presence of
G1 and G2 produced an increased cellular fluorescence com-
pared to DK1 alone (Fig. 2a and c). In contrast, the presence of
G0 and G3 did not cause the same level of fluorescence enhance-
ment. To confirm that the observed fluorescence imaging
results were based on selective galactose-ASGPr interactions,
we used a modified Hep-G2 cell line with a reduced expression
level of ASGPr (sh-ASGPr)10,24 as well as other cancer cell lines
derived from diﬀerent tissues (human cervix cancer Hela,
human lung cancer A549, human colon cancer HCT-116 and
human breast cancer MCF-7) as negative controls. With the
optimal imaging condition (40 mM/50 mg mL1), we observed
that DK1@G2 produced minimal fluorescence upon incubation
with sh-ASGPr and other cancer cells (Fig. 2b and d). Moreover,
pre-incubation of increasing free D-galactose gradually lowered
the fluorescence generated in Hep-G2 cells (Fig. S2, ESI†). We
also determined that the fluorescence intensity produced by
DK1@G2 (Fig. 2d) was in good agreement with the ASGPr
expression level of the diﬀerent cells (Fig. 2e), and that the
presence of increasing DK1 and DK1@G2 barely suppressed the
viability of Hep-G2 cells determined by two independent cell
viability counting assays (Fig. S3, ESI†). All these observations
suggest that the fluorescence imaging results observed at the
cellular level are predominantly based on galactose-ASGPr
recognition. To test the cellular localization of the glycoprobe,
confocal microscopy was used. The imaging result suggested that
DK1 was endocytosed and traﬃcked to the lysosome, which is
confirmed by co-localization with a lysotracker (Fig. S4, ESI†).
With these results in hand, we then used a mouse model
with a liver tumor to test the GO eﬀect at the tissue level. Female
athymic BALB/c nu/nu mice with Hep-G2 tumor xenograft were
Fig. 1 (a) Conditions and reagents: (I) CuSO45H2O, sodium ascorbate in
CH2Cl2/H2O (10/1, v/v), and then Et3N. (b) Schematic illustration of the
formation of the GO-based supramolecular glycocomposite for receptor-
targeting theranostics. GO = graphene oxide; CPT = camptothecin.
Fig. 2 Fluorescence imaging (a) and quantification (c) of Hep-G2 cells
with DK1 (40 mM) in the absence or presence of G0, G1, G2 and G3
(50 mg mL1). Fluorescence imaging (b) and quantification (d) of diﬀerent
human cancer cell lines using DK1@G2 (40 mM/50 mg mL1) (Hep-G2:
human liver cancer; sh-ASGPr: Hep-G2 cells with reduced expression level
of the asialoglycoprotein receptor (ASGPr); Hela: human cervix cancer;
A549: human lung cancer; HCT-116: human colon cancer; MCF-7: human
breast cancer). (e) Relative mRNA level of ASGPr of diﬀerent cells determined
by real-time quantitative polymerase chain reaction (***P o 0.001; n. d.
means not detectable). Excitation channel: 520–550 nm; emission: 580–
650 nm. Scale bar: 100 mm.
Paper Journal of Materials Chemistry B
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 0
6 
N
ov
em
be
r 2
01
5.
 D
ow
nl
oa
de
d 
on
 2
1/
04
/2
01
6 
11
:5
4:
47
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
9184 | J. Mater. Chem. B, 2015, 3, 9182--9185 This journal is©The Royal Society of Chemistry 2015
established according to a previous report,25 and the tumor,
liver, lung, heart and spleen were removed to prepare tissue
sections. By incubation of DK1 with the tumor sections in the
absence or presence of GO, we determined that DK1@G2
(40 mM/50 mg mL1, the optimal concentration used for cellular
imaging) resulted in a stronger fluorescence imaging of the
tumor than DK1 alone and other DK1@GOs (Fig. 3a and c).
We also observed that DK1@G2 selectively stained the Hep-G2
tumor xenograft and liver among other sections from the animal
model (Fig. 3b and d). This observation accords with the fact that
the galactose-selective ASGPr is only over-expressed on the tumor
and liver, but not on heart, spleen and lung (Fig. S5, ESI†).26
These results suggest that, similar to the observation on the
cellular level, the selective galactose ligand–ASGP receptor based
fluorescence imaging is enhanced by GO probably due to the
multivalent display of DK1.
From our previous work, we have demonstrated that amongst
GOs of diﬀerent sizes, G2 enhances the interaction between DK1
and a selective lectin receptor to the greatest extent.22 Spectro-
scopic measurements suggest that both the size and oxygen
content of the GO have an impact on the ligand–receptor
interactions. On the one hand, increasing the size, reduces the
oxygen content of a GO, leading to a stronger adsorption of dye
molecules but weaker adsorption of proteins. Therefore, GO with
larger sizes (such as G3 with 500–1000 nm size range) might
bind more strongly with dye molecules, whilst compromising
the binding with a lectin receptor. However, a decrease of size
increases the oxygen content and this might enhance the
association between the GO (such as G0) and a protein, whilst
decreasing the amount of glycoprobe–GO assembly, thus low-
ering the ability of the GO to augment the protein–ligand
binding. Therefore, we deduced that the medium-sized GOs
(such as G1 and G2) have an optimal size as well as oxygen
content to promote the multivalent glycoligand–receptor inter-
actions.22 Similarly, these observations may be applicable for
glycoprobe–transmembrane receptor interactions. However, due
to the complexity of the cellular environment, more sophisticated
experiments and structurally more defined GOs are required to
fully elaborate the observed GO size effect.
With this GO-based multivalent strategy, we sought to further
construct a supramolecular glycocomposite by the co-assembly
of DK1 and an anticancer drug (camptothecin – CPT) to a single
GO surface for receptor-targeting theranostics. G2 with the best
imaging effect was used to assemble with DK1 and CPT at two
different concentrations. We observed that the glycocomposites
retained their fluorescence imaging ability with selectively for
Hep-G2 cells over the other control cells tested (Fig. 4a and b).
Then, we measured the toxicity of the glycocomposites for the
cancer cells (Fig. 4). While CPT alone showed insignificant
(1 mM – low concentration group) or moderate (10 mM – high
concentration group) toxicity upon a short-time incubation (15 min)
with the cancer cells, the presence of G2 enhanced the toxicity of
the low-concentration group. This is in agreement with the
reported drug delivering ability of graphene to improve cancer
therapy.27 Interestingly, in both groups, the presence of DK1
selectively enhanced the toxicity for Hep-G2 that highly express
Fig. 3 Fluorescence imaging (a) and quantification (c) of Hep-G2 xeno-
graft slice of female athymic BALB/c nu/nu mice with DK1 (40 mM) in the
absence and presence of G0, G1, G2 and G3 (50 mg mL1). Fluorescence
imaging (b) and quantification (d) of diﬀerent tissue slices including liver,
heart, spleen and lung with DK1@G2 (40 mM/50 mg mL1). Excitation
channel: 520–550 nm; emission: 580–650 nm. Scale bar: 200 mm.
Fig. 4 Fluorescence imaging (a) and quantification (b) of diﬀerent cells
with the supramolecular DK1@G2@CPT (DK1: 40 mM; G2: 50 mg mL1).
(c) Viability of diﬀerent cells upon treatment with CPT, CPT@G2 and
DK1@G2@CPT. Excitation channel: 520–550 nm; emission: 580–
650 nm. Scale bar: 100 mm.
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ASGPr, but not for HeLa and A549 without receptor expression,
in a concentration-dependent manner. These data suggest the
suitability of using the supramolecular glycocomposites for
receptor-targeting cancer theranostics. Our supramolecular strategy
could also be extended to other biomolecular systems for specific
cellular targeting.28
Conclusions
We have determined that GO can enhance the cellular and
tissue imaging eﬀect of a small-molecule fluorescence glyco-
probe. This phenomenon could probably be reasoned by the
clustering eﬀect of GO for the fluorophore-labelled glycoligands,
increasing the avidity with transmembrane receptors. Moreover,
this non-covalent, multivalent strategy has proven suitable for
the construction of a unique supramolecular glycocomposite
comprising both the glycoprobe and an anticancer drug.
With retained fluorescence imaging ability, this glycocomposite
material displayed enhanced toxicity for liver cancer cells with
ASGPr expression, but not for the control cells without the receptor
expression. This research suggests a unique GO-based supra-
molecular strategy for receptor-targeting disease theranostics.
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